U.S. Markets open in 9 hrs 11 mins

HOOKIPA Pharma Inc. (HOOK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.33+0.01 (+0.11%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.32
Open9.22
Bid9.25 x 900
Ask9.32 x 800
Day's Range9.16 - 9.50
52 Week Range8.10 - 20.00
Volume295,898
Avg. Volume379,176
Market Cap278.168M
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
  • HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June
    GlobeNewswire

    HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June

    NEW YORK and VIENNA, Austria, June 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences: SVB Leerink CybeRx Series: Vaccine Forum, June 21 – 22, 2021JMP Securities Life Sciences Conference, June 16 – 17, 2021Fireside Chat: June 17, 10:00am ET Th

  • Hookipa Pharma's Cancer Immunotherapy Shows T-Cell Response, Interim Efficacy in Pretreated HPV16+ Cancer Settings
    Benzinga

    Hookipa Pharma's Cancer Immunotherapy Shows T-Cell Response, Interim Efficacy in Pretreated HPV16+ Cancer Settings

    Hookipa Pharma Inc (NASDAQ: HOOK) reported positive Phase 1 data from its ongoing Phase 1/2 study evaluating HB-200 to treat advanced Human Papillomavirus 16-positive (HPV16+) cancers. Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. At baseline, all patients had nearly undetectable levels of tumor-specific T cells. Within two weeks of a single dose of HB-200, all patients showed increased tumor-specific CD8+ T cell levels. ​ As of the data cut-off, (1

  • HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
    GlobeNewswire

    HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

    Novel arenaviral therapeutic HB-200 generates outstanding tumor antigen-specific CD8+ T cell responses (average of 6 percent and up to 40 percent of T cell pool)To-date, HB-201 monotherapy has shown 18 percent overall response rate and median progression-free survival of 3.45 months in heavily pretreated head and neck cancer patientsClinical data replicate pre-clinical results, showcasing the potential of HOOKIPA’s arenaviral platform to produce multiple potent cancer immunotherapies NEW YORK an